Tolerability and efficacy of targeting both mTOR and HER2 signaling in trastuzumab-refractory HER2+metastatic breast cancer

被引：0
|
作者：
Gajria, D. [1 ]
King, T. [1 ]
Pannu, H. [1 ]
Sakr, R. [1 ]
Modi, S. [1 ]
Drullinsky, P. [1 ]
Syldor, A. [1 ]
Path, S. [1 ]
Seidman, A. [1 ]
Norton, L. [1 ]
Rosen, N. [1 ]
Hudis, C. [1 ]
Chandarlapaty, S. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-P5-18-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-18-04
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Predictors of survival in patients with HER2+metastatic breast cancer (MBC) treated with trastuzumab
    Olson, E. M.
    Najita, J. S.
    Sohl, J.
    Arnaout, A.
    Winer, E. P.
    Lin, N. U.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] Evolving HER2+Metastatic Breast Cancer Landscape
    Seidman, Andrew D.
    Bardia, Aditya
    Pegram, Mark
    Rao, Ruta
    ONCOLOGY-NEW YORK, 2021, 35 (12): : 839 - 842
  • [23] HER2 Expression Impacts Trastuzumab Deruxtecan Efficacy in Breast Cancer
    不详
    CANCER DISCOVERY, 2023, 13 (10) : 2117 - 2117
  • [24] A Mechanistic Logic for Dual Targeting of HER2 and PI3K/AKT/mTOR Signaling in HER2 Amplified Breast Cancer
    Chandarlapaty, S.
    Rodrik-Outmezguine, V.
    Scaltriti, M. Maurizio
    Sakr, R.
    Will, M.
    Giri, D.
    Hudis, C.
    Baselga, J.
    King, T.
    Rosen, N.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 127 - 127
  • [25] HER2 Signaling in Breast Cancer
    Shin, Incheol
    TRANSLATIONAL RESEARCH IN BREAST CANCER, 2021, 1187 : 53 - 79
  • [26] Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer
    Watanabe, Satomi
    Yonesaka, Kimio
    Tanizaki, Junko
    Nonagase, Yoshikane
    Takegawa, Naoki
    Haratani, Koji
    Kawakami, Hisato
    Hayashi, Hidetoshi
    Takeda, Masayuki
    Tsurutani, Junji
    Nakagawa, Kazuhiko
    CANCER MEDICINE, 2019, 8 (03): : 1258 - 1268
  • [27] Quantitative measurements of HER2 expression and HER2: HER2 dimerization identify subgroups of HER2 positive metastatic breast cancer patients with different probabilities of response to trastuzumab treatment
    Huang, W.
    Lipton, A.
    Leitzel, K.
    Ali, S. M.
    Fuchs, E. M.
    Weidler, J.
    Chappey, C.
    Sperinde, J.
    Tan, Y.
    Jin, X.
    Paquet, A.
    Winston, J.
    Petropoulos, C.
    Kostler, W. J.
    Bates, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S86 - S86
  • [28] Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer
    Kim, Yoon-Jae
    Sung, Daeil
    Oh, Eunhye
    Cho, Youngkwan
    Cho, Tae-Min
    Farrand, Lee
    Seo, Jae Hong
    Kim, Ji Young
    CANCER LETTERS, 2018, 412 : 118 - 130
  • [29] Safety and Efficacy of Trastuzumab Deruxtecan for Metastatic HER2+and HER2-low Breast Cancer
    Qureshi, Zaheer
    Altaf, Faryal
    Jamil, Abdur
    Siddique, Rimsha
    Fatima, Eeshal
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (11): : 535 - 541
  • [30] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB DERUXTECAN FOR PATIENTS WITH HER2+METASTATIC BREAST CANCER
    Mudumba, R.
    Chan, H.
    Cheng, Y. Y.
    Wang, C. C.
    Correia, L.
    Ballreich, J.
    Levy, J.
    VALUE IN HEALTH, 2022, 25 (12) : S95 - S95
12345